Drug Approval | March 09, 2024
Dishman Carbogen Amcis updates on USFDA inspection at its Bavla facility
The inspection was concluded with few procedural observations
The inspection was concluded with few procedural observations
The company will provide comprehensive response to USFDA for the observations
The plan is to set up an ultramodern Solvent Recovery Plant for third party purposes
The facility will manufacture Specialty and Fine Chemicals tailored to various applications across industries such as Polymer and Water Treatment facilities
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics
ANVISA issues CGMP to Concord Biotech’s Unit I
Nectar Lifesciences has clarified that the company has no relation/connection/ association or link of any nature with the Nectar Herbs and Drugs
Earlier, he worked with Cadila Pharmaceuticals Limited, Cipla, Alkem Laboratories, and Wockhardt, and started his career with Novartis
Uppilliappan joined Dr. Lal Pathlabs in 2016 as Chief Operating Officer and later became CEO
Subscribe To Our Newsletter & Stay Updated
